DRUG TARGET ID BV

Their core work

Drug Target ID BV is a Dutch biotech SME specializing in identifying and validating drug targets for complex, multimorbid diseases — conditions where metabolic, psychiatric, and neurological dysfunction overlap. Their work involves preclinical models (iPSC-derived neurons, mouse models) and gene-level analysis to pinpoint actionable targets that pharmaceutical developers can pursue. In PRISM they contributed to stratifying psychiatric patient populations using biological markers, and in PRIME they tackled the poorly understood link between insulin resistance and neuropsychiatric conditions including Alzheimer's, compulsivity, and autism. They operate as a specialist scientific partner embedded in large, pharma-connected consortia rather than running independent research programs.

What they specialise in

How they've shifted over time

The early-period data from PRISM (2016-2019) shows no extractable keywords, but the project title reveals a focus on psychiatric patient stratification using biological markers — essentially trying to make psychiatric diagnoses more precise and biologically grounded. By PRIME (2020-2024), the keyword profile shifts dramatically toward metabolic disease: insulin, diabetes type 2, obesity, and metabolic syndrome appear alongside neuropsychiatric conditions such as Alzheimer's, compulsivity, and autism. This suggests a deliberate pivot — or expansion — from pure psychiatric biology toward the growing scientific hypothesis that insulin resistance and metabolic dysfunction are drivers of neurodegeneration and behavioral disorders. The trajectory points toward a niche at the crossroads of endocrinology and neuroscience, which is where some of the most commercially interesting drug targets currently sit.

They are moving deeper into metabolic-brain disease connections, a scientifically active and commercially valuable space — future collaborations in Alzheimer's, type 2 diabetes complications, or obesity-related CNS disorders are a natural fit.

How they like to work

Drug Target ID BV has participated exclusively as a non-coordinating partner in both projects, suggesting they prefer — or are sized for — a contributor role rather than project leadership. Their participation in IMI2 (a public-private partnership program requiring pharma industry co-funding) indicates comfort working within large, structured consortia that include major pharmaceutical companies alongside academic groups. With 41 unique partners across 11 countries from just two projects, they are clearly embedded in wide-network collaborations rather than tight, recurring partnerships.

Despite only two projects, Drug Target ID BV has built an unusually broad network of 41 unique partners spanning 11 countries — a consequence of IMI2 consortia, which tend to be large and pan-European. Their network likely includes both pharma companies and academic medical centers.

What sets them apart

Drug Target ID BV occupies a specific niche that few SMEs hold: preclinical drug target identification at the boundary of metabolic disease and neuropsychiatric disorders, an area that large pharma is investing in heavily but where in-house expertise is sparse. Their Nijmegen base places them near Radboud University Medical Centre, one of Europe's leading neuroscience institutions, which likely shapes their scientific network and approach. For a consortium needing a focused, hypothesis-driven target ID partner — rather than a broad CRO — this company offers a precise and specialized contribution.

Highlights from their portfolio

• PRIME
  The largest funded project (€400,000) and scientifically ambitious: it links insulin resistance to a remarkably wide range of conditions including Alzheimer's, autism, and compulsivity, representing a high-value drug target hypothesis space currently attracting major pharma interest.
• PRISM
  An IMI2-funded project — meaning pharmaceutical industry co-funding — focused on biological stratification of psychiatric patients, giving the company early exposure to pharma-academic consortium dynamics and translational psychiatry.